Menu
Search
|

Menu

Close
X

Anavex Life Sciences Corp AVXL.OQ (NASDAQ Stock Exchange Capital Market)

4.18 USD
+0.10 (+2.45%)
As of Jun 15
chart
Previous Close 4.08
Open 4.08
Volume 149,274
3m Avg Volume 66,018
Today’s High 4.24
Today’s Low 4.04
52 Week High 5.74
52 Week Low 1.86
Shares Outstanding (mil) 42.17
Market Capitalization (mil) 177.54
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.199
FY17
-0.328
FY16
-0.419
FY15
-0.595
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
--
5.71
Price to Book (MRQ)
vs sector
7.57
5.37
Price to Cash Flow (TTM)
vs sector
--
23.33
Total Debt to Equity (MRQ)
vs sector
0.00
16.44
LT Debt to Equity (MRQ)
vs sector
0.00
12.17
Return on Investment (TTM)
vs sector
-95.21
14.38
Return on Equity (TTM)
vs sector
-95.21
16.07

EXECUTIVE LEADERSHIP

Christopher Missling
President, Chief Executive Officer, Secretary, Director, Since 2015
Salary: $305,000.00
Bonus: --
Sandra Boenisch
Principal Financial Officer, Treasurer, Since 2015
Salary: $58,000.00
Bonus: --
Stephan Toutain
Senior Vice President - Operations, Since 2018
Salary: --
Bonus: --
Peter Donhauser
Director, Since 2017
Salary: --
Bonus: --
Claus van der Velden
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

51 W 52nd St Fl 7th
NEW YORK   NY   10019-6163

Phone: +1800.6893939

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat Alzheimer's disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer. Its research and development pipeline includes a clinical drug candidate and various compounds in different stages of pre-clinical study. Its product pipeline also includes ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1037 and ANAVEX 1066. The Company's SIGMACEPTOR Discovery Platform produces small molecule drug candidates with modes of action, based on its understanding of sigma receptors. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066 is a mixed sigma-1/sigma-2 ligand. As of September 30, 2016, the Company had not generated any revenues from its operations.

SPONSORED STORIES